| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Investment in notes receivable and warrants, related party | - | 2,425,000 |
| Investment in notes receivable and warrants | 2,425,000 | - |
| Investment in evofem preferred stock | 0 | 0 |
| Net cash used in investing activities | -2,425,000 | -2,425,000 |
| Proceeds from notes payable, related party | 678,000 | 493,000 |
| Proceeds from notes and convertible notes payable, net of offering costs | 1,674,019 | 1,504,019 |
| Repayments of note payable, related party | -608,000 | -608,000 |
| Repayments of note payable | 4,192,634 | 3,926,760 |
| Redemptions of c-1 preferred stock | - | 7,027,065 |
| Common stock, preferred stock, and warrants issued for cash, net of issuance costs | 27,338,284 | 24,777,835 |
| Cash from subscription receivable | 959,724 | 1,108,751 |
| Redemptions of a-1 preferred stock | 308,000 | 308,000 |
| Redemptions of c-1 preferred stock | 7,343,697 | - |
| Proceeds from exercises of warrants | 0 | - |
| Net cash provided by financing activities | 18,197,696 | 16,013,780 |
| Stock-based compensation | 473,311 | 473,311 |
| Stock-based compensation from asset purchase | 10,000 | 10,000 |
| Amortization of debt discount - note payable | 1,646,697 | 1,412,530 |
| Amortization of debt discount - note receivable, related party | 208,009 | 99,897 |
| Change in fair value of derivative liability | -14,287 | -14,125 |
| Impairment of evofem f-1 preferred stock | 23,001,919 | - |
| Credit loss on evofem notes | 350,000 | - |
| Accounts receivable | -4,253 | -3,692 |
| Prepaid expenses | 59,237 | 59,237 |
| Deposits | 157,026 | 128,274 |
| Settlement liability | - | 0 |
| Other assets | 75,229 | - |
| Inventory | -4,673 | -3,628 |
| Accounts payable and accrued expenses | -1,620,353 | -2,552,013 |
| Net loss | -37,555,792 | -13,348,123 |
| Change in fair value of evofem warrants | -2,448,570 | 63,211 |
| Depreciation expense | 202,464 | 135,498 |
| Amortization of intangible assets | 2,500 | 1,667 |
| Loss on note exchange agreement | 0 | 0 |
| Modification of warrants for debt issuance costs | 0 | - |
| New principal from extension of notes, net of debt discount | 0 | 0 |
| Settlement liability | 0 | - |
| Net cash used in operating activities | -16,442,686 | -14,098,132 |
| Net increase (decrease) in cash | -669,990 | - |
| Cash and cash equivalents at beginning of period | 833,031 | - |
| Net decrease in cash | - | -509,352 |
| Cash and cash equivalents at end of period | 163,041 | - |
Aditxt, Inc. (ADTX)
Aditxt, Inc. (ADTX)